Cantargia AB (publ) is a clinical-stage biotechnology company dedicated to developing antibody-based therapies for life-threatening diseases, with a primary focus on cancer and inflammatory conditions. The company's research centers on the interleukin-1 receptor accessory protein (IL1RAP), a target molecule involved in various cancer forms and inflammatory processes. Cantargia's lead candidate, nadunolimab (CAN04), is being investigated in multiple clinical trials for various cancers, including pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. A second project, CAN10, is an antibody targeting IL1RAP for the treatment of autoimmune and inflammatory diseases, currently in late preclinical development.
Serves as the central hub for research and development, clinical operations, corporate administration, financial management, and strategic business development.
Located within Medicon Village, a leading Scandinavian life science park, offering access to advanced research infrastructure, shared lab facilities, and a collaborative ecosystem with other biotech companies and academic institutions.
A dynamic, science-driven, and collaborative work environment. Cantargia fosters innovation, teamwork, and a strong focus on advancing treatments for patients with life-threatening diseases, encouraging scientific rigor and open communication.
The Lund headquarters is crucial for Cantargia's core research activities, management of its global clinical trial programs, intellectual property development, and strategic positioning within Europe's biotechnology landscape.
Cantargia AB manages its global operations, primarily its extensive clinical development programs, from its headquarters in Lund, Sweden. The company collaborates with clinical trial sites, contract research organizations (CROs), and academic institutions across North America, Europe, and potentially other regions to advance its therapeutic candidates. Its engagement with regulatory authorities such as the FDA (USA) and EMA (Europe) also underscores its international operational scope. Business development activities are also global, seeking partnerships and collaborations worldwide.
Medicon Village, Scheeletorget 1
Lund
Skåne County
Sweden
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cantargia AB' leadership includes:
Cantargia AB has been backed by several prominent investors over the years, including:
In the past 12 months, Cantargia AB appointed Patrik Renblad as the new Chief Financial Officer, succeeding Bengt Jöndell who retired from the position.
Discover the tools Cantargia AB uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cantargia AB typically uses the 'firstname.lastname@cantargia.com' email format for its employees. This is a common pattern for companies in Sweden and globally.
firstname.lastname@cantargia.com
Format
goran.forsberg@cantargia.com
Example
90%
Success rate
Cantargia AB Press Releases • May 23, 2024
Cantargia announced it will present updated efficacy results from the CANFOUR phase IIb clinical trial, investigating nadunolimab plus chemotherapy in first-line pancreatic cancer (PDAC), at the ASCO Annual Meeting 2024....more
Cantargia AB Press Releases • April 25, 2024
Cantargia released its Q1 2024 financial results, highlighting progress in its clinical trials, particularly the CANFOUR study with nadunolimab, and advancements in the CAN10 project....more
Cantargia AB Press Releases • April 8, 2024
Cantargia presented new preclinical findings at the American Association for Cancer Research (AACR) Annual Meeting 2024, further elucidating the mechanisms of action of its lead drug candidate nadunolimab (CAN04)....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cantargia AB, are just a search away.